BCCM
AVTX icon

Blue Clay Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Blue Clay Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2
Closed -$11K – 107
2016
Q2 		$11K Sell
2
-13
-87% -$118K 0.01% 102
2016
Q1 		$156K Hold
15
– – 0.15% 107
2015
Q4 		$140K Buy
+15
New +$164K 0.12% 105

Other funds holding AVTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Blue Clay Capital Management's AVTX Position: Q3 2016 in Review

Blue Clay Capital Management sold out of Avalo Therapeutics (AVTX) in Q3 2016, closing a stake of 2 shares — an estimated $11K sold.

Blue Clay Capital Management first reported a position in AVTX in Q4 2015 and held it in 3 quarters. The position peaked at $156K in Q1 2016. 4 funds tracked by Wall St. Rank hold AVTX as of Q3 2016.

  • Blue Clay Capital Management reported no remaining Avalo Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Blue Clay Capital Management sold 2 Avalo Therapeutics shares in Q3 2016, an estimated $11K.
  • Blue Clay Capital Management first reported a position in Avalo Therapeutics in Q4 2015 and held it in 3 quarters.
  • Blue Clay Capital Management's Avalo Therapeutics position peaked at $156K in Q1 2016.
  • 4 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2016.

Based on Blue Clay Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.